Brief: Ipsen Announces Positive Dysport Phase III Results For Migraine Prevention
09/07/2026 06:11
BRIEF-Ipsen Announces Positive Dysport Phase III Results For Migraine Prevention July 9 (Reuters) - Ipsen SA IPN.PA:
ANNOUNCES POSITIVE PHASE III TOPLINE RESULTS FOR DYSPORT IN MIGRAINE PREVENTION
DYSPORT PHASE III TRIALS MEET PRIMARY ENDPOINTS IN MIGRAINE PREVENTION
Source text: ID:nGNE54j91B
Further company coverage: IPN.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 7785110;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio